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Introduction: Fever is associated with a poor outcome in severely brain-injured patients, and its control is one of
the therapies used in this condition. But, fever suppression may promote infection, and severely brain-injured patients
are frequently exposed to infectious diseases, particularly ventilator-associated pneumonia (VAP). Therefore, we
designed a study to explore the role of a fever control protocol in VAP development during neuro-intensive care.
Methods: An observational study was performed on severely brain-injured patients hospitalized in a university ICU. The
primary goal was to assess whether fever control was a risk factor for VAP in a prospective cohort in which a fever
control protocol was applied and in a historical control group. Moreover, the density of VAP incidence was compared
between the two groups. The statistical analysis was based on a competing risk model multivariate analysis.
Results: The study included 189 brain-injured patients (intervention group, n = 98, and historical control group, n = 91).
The use of a fever control protocol was an independent risk factor for VAP (hazard ratio 2.73, 95% confidence interval
(1.38, 5.38; P = 0.005)). There was a significant increase in the incidence of VAP in patients treated with a fever control
protocol (26.1 versus 12.5 VAP cases per 1000 days of mechanical ventilation). In cases in which a fever control protocol
was applied for >3 days, we observed a higher rate of VAP in comparison with the rate among patients treated
for ≤3 days.
Conclusions: Fever control in brain-injured patients was a major risk factor for VAP occurrence, particularly when
applied for >3 days.Introduction
In severely brain-injured patients, the incidence of fever
in the first week of hospitalization approaches 87% [1].
Numerous studies have noted that fever in these patients
is associated with a prolonged length of stay in the in-
tensive care unit (ICU) and hospital, severe physical de-
pendency, cognitive impairment and increased mortality
[2,3]. Thus, fever control is a common therapy used to
treat patients with severe brain injuries [4]. Nevertheless,
specific guidelines concerning the optimal delay, length,
means and target of temperature control are lacking [4,5].* Correspondence: yoann.launey@chu-rennes.fr
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unless otherwise stated.From another perspective, several experimental and
clinical studies that have assessed fever control in other
diseases have suggested that there are harmful effects as-
sociated with a fever control strategy [6-9]. These adverse
effects of fever control, notably shivering, infectious dis-
eases and/or hypotension, are negative factors affecting
the prognoses of brain-injured patients [10,11]. In fact,
fever, which is typically defined by an elevation of the core
temperature above 38.2?C [12,13], may be an adaptive
response to injury when an infectious disease is on-
going [14]. Nosocomial infections, particularly ventilator-
associated pneumonia (VAP), are frequently observed in
severely brain-injured patients, affecting from 8% to more
than 70% of patients [15,16]. Therefore, we designed this
study to define the role of a fever control protocol in VAP
development during neuro-intensive care.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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This observational study was conducted between January
2008 and December 2009 in the surgical ICU of a uni-
versity hospital, which received, among others, severely
brain-injured patients. The criteria for selection included
a severe brain injury (traumatic brain injury (TBI), sub-
arachnoid hemorrhage (SAH), or intracranial hemorrhage),
a Glasgow Coma Scale score ≤8 and a need for mechanical
ventilation (MV) for 48 hours or longer. Each selected pa-
tient underwent chart review. Patients who had aspiration
pneumonia at admission or a brain computed tomography
(CT) scan without any lesion or who received MV for less
than 48 hours were excluded. This study was submitted to
the local ethical committee of Rennes University Hospital
(CHU Pontchaillou, Rennes, no. 14.45), which stated that
no patient consent was needed.
In 2008, Greer et al. suggested that fever had a dele-
terious effect in brain-injured patients and that there
was an evidence-based need to confirm the potential
benefit of fever control in this population [2]. Conse-
quently, from 1 January 2009 until 31 December 2009, a
fever control protocol was applied in cases in which the
core body temperature was >38.2?C. Because the fever
control protocol was the only therapeutic change, pa-
tients admitted from 1 January 2008 to 31 December 31
2008 served as historical controls. In the fever-control
group, patients were prospectively and consecutively in-
cluded, whereas in the historical control group, patients
were identified and selected from the list of admissions
to our ICU.
The primary endpoint was to assess whether fever
control was a risk factor for VAP. The secondary end-
points were the density of incidence and the incidence
of VAP, both nosocomial urinary tract infections (UTIs)
and catheter-related bloodstream infections (CRBIs), the
duration of MV, the length of stay in the ICU, and the
mortality rate.
Patient management
During the two study periods, brain-injured patients
were similarly managed according to identical local pro-
tocols based on international guidelines [17,18]. The two
major objectives were as follows: 1) to infuse neuroseda-
tion combining midazolam and opioids; and 2) to main-
tain cerebral perfusion pressure ≥70 mmHg. All the
patients were orotracheally intubated; VAP prevention
measures included hand washing with alcohol based anti-
septic, a 30? semi-recumbent patient position, MV with
positive end-expiratory pressure >5 mmHg, and oral care
based on local application of povidone-iodine solution six
times daily [15]. Selective digestive decontamination or
subglottic drainage was not performed, and ulcer prophy-
laxis was not systematically administered. The core body
temperature was continuously monitored with a rectalthermal probe (Mon-a-Therm? , Covidien, Mansfield, MA,
USA).
Fever control intervention was applied in cases in
which the body core temperature was >38.2?C [12]. This
protocol was established based on previously published
studies [4,19,20] and successively included the following:
external cooling, an infusion of 500 mL of cooled (4?C)
saline serum and enteral administration of acetamino-
phen. A neuromuscular blocker (cisatracurium) was also
used if shivering occurred. The objective was to reach a
core body temperature of 36?C to 38.2?C.
Data collection and definitions
Gender, age, body mass index, the reason for ICU ad-
mission, a history of smoking, a positive alcohol test at
admission and CT scan-identified lung contusions in-
volving more than one lobe were recorded for each pa-
tient at the time of admission to the ICU. The severity
of the brain injury was assessed at admission using the
Glasgow Coma Scale score and the Simplified Acute
Physiological Score II (SAPS II) [21].
We collected the daily minimum (Tmin) and maximum
(Tmax) body core temperature and calculated the mean
daily temperature as (Tmax + Tmin)/2 during the first
eight days of ICU hospitalization. We reported the delay
between ICU admission and the initiation of the fever
control protocol, the length of application of the fever
control protocol and mortality at ICU discharge. Anti-
biotic prophylaxis, neuromuscular blocker agents, manni-
tol and thiopental use was reported for all patients.
Additionally, acute respiratory distress syndrome (ARDS),
defined as previously [22], and microbiological findings for
VAP were reported.
VAP was defined as new and persistent pulmonary in-
filtrates on a chest radiograph occurring after 48 hours
of MV, combined with at least two of the following cri-
teria: 1) purulent tracheal secretions and/or body core
temperature >38?C and/or leukocytosis >10,000/mm 3 or
leukopenia <3,000/mm3; and 2) microbiological confirm-
ation via an endotracheal aspirate quantitative culture
growing ≥106 colony forming units (cfu)/mL [23]. The
occurrence of VAP was reported and expressed as the
density of incidence, defined as the number of VAP
cases per 1,000 ventilator-days. We also defined early-
onset VAP as VAP that occurred ≤5 days after admission
and late-onset VAP as VAP diagnosed >5 days, according
the American Thoracic Society criteria [24].
UTIs and CRBIs were defined according to the CDC
guidelines [25,26].
Statistical analysis
The categorical parameters are expressed as number and
frequency. The quantitative parameters are expressed as
the mean (standard deviation) if there was a normal
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wise. The categorical parameters were compared using
the Chi-square test or, when necessary, Fisher's exact
test. The quantitative parameters were compared using
the two-tailed t-test (when normally distributed) or with
the Mann ? Whitney U test. The temperature value was
recorded on the date of the VAP diagnosis. To deter-
mine risk factors for VAP occurrence, we used a com-
peting risk model, as proposed by Fine and Gray [27].
VAP before the 28th day of hospitalization in the ICU
was an event of interest but could be precluded by death
before the 28th day of hospitalization. Patients were
therefore observed from the day of hospitalization to the
occurrence of VAP before the 28th day of hospitalization
in the ICU, to death before the 28th day of hospitalization,
or to censoring (hospital discharge while living, without
VAP occurrence at day 28 or before). We first compared
patient characteristics according to whether the fever con-
trol protocol was used to identify potential confounding
factors existing before VAP occurrence. A univariate ana-
lysis was first performed. Variables with P-values <0.20
were then included in the multivariate competing risk
model, and a backward selection was applied. The model
was adjusted for the risk factors selected according to use
of the fever control protocol. By stratifying the duration of
fever control, we analyzed the effect of the duration of
fever control on VAP occurrence. The adjusted hazard ra-
tios (HRs) and their corresponding 95% confidence inter-
vals (CIs) were calculated, and the cumulative incidence
curves for VAP were determined using the Nelson-Aalen
non-parametric estimator. By stratifying the fever control
duration, we could also describe the impact of the fever
control duration on VAP based on the cumulative inci-
dence curve with the Nelson-Aalen non-parametric es-
timator. A two-sided P-value <0.05 was considered
statistically significant. The statistical models were built
using SAS 9.3 (SAS Institute, Inc., Cary, NC, USA) and
R Core Team (2012) software (R: A language and en-
vironment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria).
Results
During the study period, 331 brain-injured patients were
screened, and 189 were included (intervention group,
n = 98; historical control group, n = 91) (Figure 1). The pri-
mary characteristics of the patients are presented in Table 1.
The proportion of subarachnoid hemorrhaging was signifi-
cantly higher in the intervention group than in the his-
torical control group (28% versus 14%, respectively; P =
0.006). The clinical characteristics are reported in Table 2.
Management of the fever control protocol
All patients in the intervention group were treated with
the fever control protocol when their fever was >38.2?C.The delay before its effective application was less than
24 hours, and its median duration was four days (range,
two to six days). The daily mean temperature curves for
each group are displayed in Figure 2.
The density of the incidence of VAP was significantly in-
creased in the intervention group beginning on ICU day 5
(26.1 versus 12.5 VAP cases per 1,000 days of ventilation;
P <0.001). The incidence of VAP was 38% (n = 37) versus
12% (n = 11) for the intervention group and historical con-
trol group, respectively. The mean delay for VAP occur-
rence was similar in the two groups (8 ? 4 days). The
mean length of MV was significantly increased in the
intervention group (15 ? 11 versus 10 ? 7 days, P <0.001).
Methicillin-sensitive Staphylococcus aureus (MSSA), Strep-
tococcus pneumoniae and Haemophilus influenzae com-
prised 80% of the microbiological findings. The
microbiological findings are detailed in Table 3. Consider-
ing the VAP-onset delay, we reported 10 early-onset VAP
cases in the intervention group compared with 5 in the
historical control group and 27 late-onset VAP cases in
the intervention group compared with 6 in the historical
control group.
The densities of incidence of UTIs and CRBIs were
not significantly different between the intervention and
the historical control groups (9.7 versus 14.7 UTIs per
1,000 urinary catheter-days, respectively; P = 0.9; 3.9 versus
1.6 CRBIs per 1,000 catheter-days, respectively; P = 0.19).
The mortality rate also did not differ between the two
groups (34% in the intervention group versus 23% in the
historical control group; P = 0.107).
In the univariate analysis (Table 4), the patients who
developed VAP were significantly younger, used tobacco
more frequently and had more extensive lung injury at
admission to the ICU. Application of the fever control
protocol was a major risk factor for developing VAP (HR
3.06; 95% CI (1.58, 5.94)). In the multivariate analysis,
the competing risk model was built after adjustment of
the HR for a history of smoking, age, the SAPS II score,
pentothal use and the use of neuromuscular blocker
agents. The use of the fever control protocol was the
only significant independent risk factor for VAP occur-
rence (HR 2.73, 95% CI (1.38, 5.38)) (Table 4). The cumu-
lative incidence function curves for VAP are displayed in
Figure 3. The risk of VAP appeared to be higher when
the duration of the fever control protocol was >3 days
(Figure 4).
Discussion
In this study, we found that the use of a fever control
protocol during the early management of critically brain-
injured patients was associated with an increased risk of
VAP. During ICU hospitalization of brain-injured patients,
sepsis and VAP are major causes of death [23]. In particu-
lar, VAP is estimated to occur in 25% to 70% of critically ill
Figure 1 Flowchart of the study inclusion scheme. MV: mechanical ventilation.
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brain-injured patients was 26%, and the microbiological
results were relatively similar to those of previous studies
[15,30,31], which predominantly found the following
microorganisms: MSSA, Haemophilus influenzae and
Streptococcus pneumoniae. It is noteworthy that VAP in-
cidence could be underestimated in the intervention
group because fever is a clinical sign of VAP; conse-
quently, the difference in VAP occurrence between the
two groups could be minimized. The deleterious effect of
such infections has recently been reported in two meta-Table 1 Baseline characteristics
Baseline characteristics Intervention group Control group P-value
Number = 98 Number = 91
Age 45 (25 to 57) 53 (27 to 66) 0.022
Gender (male) 72 (73%) 64 (70%) 0.631
BMI 25 ? 4 24 ? 5 0.123
Reason for admission 0.012
TBI 64 (65%) 61 (67%)
SAH 27 (28%) 13 (14%)
ICH 7 (7%) 17 (19%)
Smoking 38 (39%) 23 (25%) 0.048
Positive alcohol test 11 (11%) 14 (15%) 0.399
Lung contusion 28 (29%) 17 (19%) 0.111
GCS 6 (3 to 8) 6 (3 to 7) 0.338
SAPS II 49 ? 11 53 ? 14 0.013
BMI: body mass index; GCS: Glasgow Coma Scale; ICH: intracranial hemorrhage;
SAH: subarachnoid hemorrhage; SAPS II: Simplified Acute Physiology Score II;
TBI: traumatic brain injury.analyses, which showed that VAP was associated with in-
creased mortality [32,33]. However, in a subgroup of
trauma patients, no significant increase in mortality was
observed [33].
VAP in severely brain-injured patients has a different
pattern than in other critically ill patients. Several factors
favor the development of VAP. In brain-injured patients,
VAP typically occurs early in the ICU stay, between day
5 and day 11 after hospitalization. The presence of ab-
normal protection of the glottal area and consecutive
early micro-inhalation is typically suggested to explain
the occurrence of VAP. These aspirations predominantly
contain oropharyngeal bacteria from the commensal
flora of the patient, as shown by Ewig et al. [34]. In this
context, pneumonia results from extensive tracheal and
bronchial inocula in patients with altered immune re-
sponses and ventilation-related impairment (including
due to an endotracheal tube, sedation, or neuromuscular
blockers) [35,36].
Fever may be an adaptive response to injury, particu-
larly in cases of ongoing infectious disease. When this
response is suppressed, several studies have indicated an
increased risk of infectious disease and, especially, VAP.
In particular, randomized studies have shown an in-
creased rate of VAP in groups treated with therapeutic
hypothermia [37,38]. For instance, although the method-
ology is debatable, a meta-analysis including eight stud-
ies of patients with TBIs reported an increased rate of
VAP in the group receiving therapeutic hypothermia
(OR 2.37, 95% CI (1.37, 4.10)) [37]. Similarly, Geurts
et al. found an increased risk of VAP (risk ratio 1.44,
95% CI (1.10, 1.90)) and sepsis (risk ratio 1.80, 95% CI






Number = 98 Number = 91
ARDS, yes 4 (4%) 2 (2%) 0.684
Antibiotic prophylaxis 43 (44%) 43 (47%) 0.645
NMB agents 13 (13%) 5 (5%) 0.116
Pentothal use, yes 39 (40%) 19 (21%) 0.005
Mannitol use, yes 49 (50%) 21 (23%) <0.001
ICU length of stay, days 17 ? 13 11 ? 8 <0.001
Mortality, number (%) 23 (23%) 31 (34%) 0.107
ARDS: acute respiratory distress syndrome; ICU: intensive care unit; NMB:
neuromuscular blocker.
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thermia, regardless of what surface or endovascular
cooling devices were used [38].
To overcome this adverse effect, normothermia-targeted
temperature management has been suggested. However,
data on the effects of normothermia in neurologically in-
jured patients are limited. Several studies have investigated
and compared the efficacy of different devices in maintain-
ing normothermia but, despite their conclusions, have re-
ported no difference in adverse effects. These studies were
not designed to evaluate the rate of infection [39-41].
Additionally, Puccio et al. retrospectively compared the ef-
fects of a normothermia protocol on TBI managementFigure 2 Mean daily body core temperature curves for the first eight
standard deviation are displayed for the control group and the intervention[42]. They found a beneficial effect on intracranial pres-
sure and on the duration of intracranial hypertension
episodes in the normothermia group. The systematic ini-
tiation of a normothermia protocol, even prophylactic-
ally, allowed fever control and possibly attenuation of
secondary brain injuries. Similarly, Badjatia et al. assessed
the effect of normothermia in SAH in a case? control
study [11]. They found better fever control, without a sig-
nificant increase in the rate of VAP (a 58% rate of VAP in
the therapeutic normothermia group versus 51% in the
historical control group; P = 0.08).
In our study, we observed that a sustained interven-
tion for >3 days was more likely to aggravate the inci-
dence of VAP compared with an intervention with a
duration of ≤3 days. To the best of our knowledge, no
previous study has investigated the effect of the duration
of normothermia. It appears that the targeted body
temperature does not affect VAP occurrence; however,
counteracting the physiological fever response to stress
and its duration may be a key factor in the increased oc-
currence of VAP. More specifically, although fever is
deleterious in the short and medium term in brain-
injured patients, fever control, whether by hypo- or nor-
mothermia, allows reduction of the intracranial pressure
at the expense of increased susceptibility to infections.
Moreover, in therapeutic hypothermia, the hypothesized
anti-inflammatory effect has been associated with im-
paired cellular and humoral immunity [43]. Unfortunately,days of ICU stay. Upper (dashed line) and lower (dark line) limits of
group, respectively.





Number = 62 Number = 48 Number = 14
Gram-positive cocci
MSSA 22 17 5
MRSA 1 0 1
Streptococcus pneumoniae 11 8 3
Streptococcus anginosus 1 0 1
Gram-negative bacilli
Haemophilus influenzae 17 14 3
Escherichia coli 3 3 0
Moraxella catarrhalis 1 0 1
Klebsiella oxytoca 1 1 0
Proteus mirabilis 1 1 0
Citrobacter freundii 1 1 0
Enterobacter cloacae 1 1 0
Acinetobacter baumannii 1 1 0
MSSA: methicillin-sensitive Staphylococcus aureus; MRSA: methicillin-resistant
Staphylococcus aureus; VAP: ventilator-associated pneumonia.
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brain physiology in fever control targeting normothermia.
Concerning the strengths and limitations of our study,
the survey of major nosocomial infections in our ICU
was prospective starting in 2002, and the diagnostic criteria
did not change between the two study periods. Although
the use of competing risk models in the multivariate ana-
lysis ensured the strength of our study, the major limita-
tion is the design of the study, which used a historical
control group, consequently implying limited matching
between the two study groups. The interpretation of theTable 4 Risk factors for VAP occurrence before day 28 (univa
Parameters Univariate analysis
HR 95% CI (HR) P-
Age 0.97 (0.95, 0.98) <
Gender (male) 1.82 (0.88, 3.78) 0
BMI 0.99 (0.93, 1.05) 0
Smoking 1.89 (1.09, 3.30) 0
Alcohol intake 0.85 (0.35, 2.09) 0
Lung contusion 2.41 (1.37, 4.24) 0
GCS 0.97 (0.85, 1.12) 0
SAPS II 0.98 (0.95, 1.00) 0
NMB agents 2.11 (0.97, 4.61) 0
Mannitol 1.25 (0.72, 2.17) 0
Thiopental 1.36 (0.78, 2.38) 0
Fever control 3.06 (1.58, 5.94) <
BMI: body mass index; GCS: Glasgow Coma Scale; NMB: neuromuscular blocker; SAPS Iresults should consider the difference in the mean age and
the reason for admission between each group, particularly
the higher number of SAH in the control group. Addition-
ally, we have accounted for the confounding factors that
may impact the occurrence of VAP, but red blood cell
transfusion, level of sedation and antibiotic use during ICU
stay were not reported. Head of bed elevation was not re-
ported but standard care in our ICU uses a 30? semi-
recumbent patient position. Finally, the fever threshold
chosen to start the fever control protocol should be dis-
cussed; certain studies have used a temperature threshold
of 38?C to start fever control interventions, but solid evi-
dence to clearly support this threshold is lacking.Conclusions
Protocol-based control of fever in patients with severe
head injuries is associated with an increased risk of VAP
during the patients? ICU stay. Our results suggest that
when targeted normothermia is used, the probability of
developing an infectious fever within 72 hours is low.
However, if fever occurs later, the probability of an infec-
tious fever is higher and should alert intensivists to an
ongoing infection. Because data on the impact of fever
control and its side effects on the outcome of brain-
injured patients are scarce, a large randomized study is
required.Key messages
The fever control in severely brain-injured patients is a
major risk factor for VAP. Moreover, the VAP rate ap-
pears to be higher if fever control lasts longer than 3
days.riate and multivariate analyses)
Multivariate analysis
value HR 95% CI (HR) P-value
0.001 0.97 (0.95, 0.98) <0.001
.110
.730




.068 1.01 (0.98, 1.04) 0.590
.061
.430
.270 0.95 (0.53, 1.69) 0.950
0.001 2.73 (1.38, 5.38) 0.005
I: Simplified Acute Physiology Score II; VAP: ventilator-associated pneumonia.
Figure 3 Cumulative incidence function curve for VAP occurrence according to fever control protocol management. The non-parametric
estimator according to Nelson-Aalen. VAP: ventilator-associated pneumonia.
Figure 4 Cumulative incidence function curve for VAP occurrence according to the duration of the fever control protocol when applied.
VAP: ventilator-associated pneumonia.
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